Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
Status:
Not yet recruiting
Trial end date:
2024-11-02
Target enrollment:
Participant gender:
Summary
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist
Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have
been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg
level >1000 (3 log10) IU/mL at screening. The study will also evaluate if TLR8 stimulation
with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)